Phase 2 N=233 The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
Pelvic Inflammatory Disease
Primary: Clearance of Anaerobic Organisms From the Endometrium — 14; 18; 7; 1 participants — p=0.046
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=76 Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Pelvic Inflammatory Disease
Primary: Response Rate (Clinical Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃…
Phase 3 N=460 A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
Pelvic Inflammatory Disease
Primary: Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population — 152; 155; 42; 35 participants
N/A N=286 Technology Enhanced Community Health Nursing (TECH-N) Study
Pelvic Inflammatory Disease (PID)
Primary: Number of Participants With Positive Sexually Transmitted Infection Test (STI) — 6; 13 Participants — p=0.070
N/A N=403 Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
Pneumonia · Pelvic Inflammatory Disease
Primary: Number of Participants With Treatment-Related Adverse Events — 39; 7 Participants
N/A N=64 Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05
Phase 2 N=15 Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
Diabetes · Infection
Primary: Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With…
N/A N=9 Surgical Treatment of Pelvic Joint Instability in Patients With Severe Pelvic Girdle Pain After Pregnancy and Trauma
Pelvic Joint Instability · Pelvic Pain
Primary: Oswestry Disability Index (ODI) — 54; 37 units on a scale
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
N/A N=36 Program to Overcome Pelvic Pain Study
Pelvic Pain · Chronic Pelvic Pain · Recurrent Pelvic Pain
Primary: Number of Randomized Participants Who: a) Are Retained at 8 Weeks, b) Attend at Least 75% of Intervention Classes, c) Demonstrate at Least Moderate Intervention…
N/A N=69 Novel Web-based, Self-directed Intervention for Chronic Pelvic Pain
Chronic Pelvic Pain · Endometriosis
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form (SF) 4a Between Groups — 59.2; 63.4 t-scores — p=0.038
N/A N=50 Continence Pessary Versus Disposable Intravaginal Device Trial
Female Stress Incontinence
Primary: Treatment Success — 8; 9 Participants
N/A N=24 Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure Rate — 18 Participants
Phase 2 N=100 Dilute Povidone-iodine Irrigation vs No Irrigation for Children With Acute, Perforated Appendicitis
Acute, Perforated Appendicitis
Primary: Number of Participants With Postoperative Intra-abdominal Abscess — 6; 8 Participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
N/A N=671 Prevention of Peritonitis in Peritoneal Dialysis
Kidney Failure, Chronic · Peritoneal Dialysis-associated Peritonitis · Dialysis Capd Infection
Primary: Time to the First Dialysis-associated Peritonitis Episode in the Retraining Group and the Control Group — 381; 368 Days to first peritonitis episode — p=0.51
Phase 2 N=49 Vaginal Diazepam for the Treatment of Female Pelvic Pain
Pelvic Floor Disorders · Pelvic Pain
Primary: Visual Analog Scale (VAS) for Pain — 50; 39 score on a scale — p=0.62
Phase 3 N=255 Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location
Persistent Pregnancy of Unknown Location · Ectopic Pregnancy
Primary: Number of Participants With Uneventful Clinical Resolution of a Pregnancy of Unknown Location Without Change From the Initial Management Strategy — 31; 42; 45 Participants
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
N/A N=705 Women's Improvement of Sexual Health (WISH) Demonstration Project
Sexually Transmitted Disease · Bacterial Vaginosis · Vaginal Candidiasis
Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants
Phase 4 N=242 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Urinary Tract Infections
Primary: Urinary Tract Infection — 11; 12 UTI
N/A N=351 Point of Care Diagnosis of Vaginal Infections
Vaginitis · Bacterial Vaginosis · Yeast Vaginitis
Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001
N/A N=2 Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Pyoderma Gangrenosum · Crohn's Disease · Ulcerative Colitis
Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants
N/A N=58 Intra-vaginal Electrical Stimulation Device Compared to Sham Device for Chronic Pelvic Pain
Pelvic Pain
Primary: Change From Baseline in Pain on the Visual Analog Scale (VAS) at Week 12 — -8.5; -7.4 units on a scale — p=0.8979
N/A N=103,039 Adolescent Sexually Transmitted Infection Screening in the Emergency Department
Gonorrhea · Chlamydia
Primary: GC/CT Detection Rates — 15.2; 12.1; 11 No. of patients with positive GC/CT
N/A N=107 Phenazopyridine for Confirmation of Ureteral Patency
Cystoscopy
Primary: Time to Visualize Ureteral Urine Flow Intraoperatively Measured by Timing in the Operating Room — 160; 173 seconds — p=0.77
Phase 2 N=25 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
Phase 4 N=163 Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)
Urinary Tract Infection
Primary: Urinary Tract Infections — 18; 10 participants
Phase 3 N=567 Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities
Chlamydial Infection
Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…
N/A N=120 RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis
Chronic Endometritis
Primary: The Conversion Rate of CE (From Positive to Negative) — 89.8; 12.7 Percentage of participants